Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

Cancer Med. 2021 Oct;10(20):6933-6936. doi: 10.1002/cam4.4254. Epub 2021 Sep 8.

Authors

Affiliations

¹ Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
² Department of Hematologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Abstract

Keywords: NGF-MRD; mass spectrometry; multiple myeloma.

Publication types

Comparative Study
Letter

MeSH terms

Bone Marrow / metabolism
Bone Marrow / pathology
Chromatography, Liquid / methods
Flow Cytometry / methods*
Humans
Immunoglobulin A / blood
Immunoglobulin G / blood
Immunoglobulin Light Chains / blood*
Induction Chemotherapy / methods
Maintenance Chemotherapy / methods
Mass Spectrometry / methods
Multiple Myeloma / blood*
Multiple Myeloma / drug therapy
Multiple Myeloma / pathology
Myeloma Proteins / analysis
Neoplasm, Residual / blood*
Spectrometry, Mass, Electrospray Ionization / methods*
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

Substances

Immunoglobulin A
Immunoglobulin G
Immunoglobulin Light Chains
Myeloma Proteins
multiple myeloma M-proteins